The first phase 1 trial of varying doses (0.3–10 mg/kg) of nivolumab, a fully human IgG4 anti–PD-1-blocking antibody, in 39 patients with advanced MEL, CRC, CRPC, NSCLC, or RCC was reported in 2010 19. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.